{
    "data": [
        {
            "id": "4654954",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-29T15:00:01-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404145528/image_1404145528.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: LEQEMBI's $10 Billion Potential",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105994",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "505574",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4654954-biogen-laqembis-10-billion-potential"
            }
        },
        {
            "id": "4649320",
            "type": "article",
            "attributes": {
                "publishOn": "2023-11-08T16:03:41-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/479387022/image_479387022.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen's Uncertain Strategic Pivots Amidst MS Market Challenges",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "500458",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4649320-biogens-uncertain-strategic-pivots-amidst-ms-market-challenges"
            }
        },
        {
            "id": "4638195",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-29T16:46:22-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401699330/image_1401699330.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "489790",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4638195-biogen-revised-revenue-forecasting-to-2030-new-ceo-faces-major-challenges"
            }
        },
        {
            "id": "4634027",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-09T10:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Eyes On CPI, New iPhones, And Google Vs. U.S. Trial",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4634027-stocks-to-watch-eyes-on-cpi-new-iphones-and-google-vs-us-trial"
            }
        },
        {
            "id": "4633097",
            "type": "article",
            "attributes": {
                "publishOn": "2023-09-05T08:27:58-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1655079616/image_1655079616.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "483237",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4633097-biogen-leqembi-could-boost-prospects-until-acquisition-comes-into-play"
            }
        },
        {
            "id": "4627497",
            "type": "article",
            "attributes": {
                "publishOn": "2023-08-11T14:23:56-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1435012411/image_1435012411.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103833",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "477351",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4627497-biogen-q2-2023-analysis-reata-acquisition-financials-and-alzheimers-prospects"
            }
        },
        {
            "id": "4615988",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-09T23:52:19-04:00",
                "isLockedPro": false,
                "commentCount": 41,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1395741078/image_1395741078.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen And Alzheimer's Disease: Too Early To Celebrate",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "97526",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "469194",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615988-biogen-stock-alzheimers-disease-too-early-to-celebrate"
            }
        },
        {
            "id": "4615723",
            "type": "article",
            "attributes": {
                "publishOn": "2023-07-07T10:20:40-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/97873871/image_97873871.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102730",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "468443",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4615723-will-watershed-moment-for-alzheimers-propel-biogen-stock-higher"
            }
        },
        {
            "id": "4613818",
            "type": "article",
            "attributes": {
                "publishOn": "2023-06-27T05:14:31-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1440458360/image_1440458360.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: Mounting Expectations Ahead Of Leqembi Decision",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "466389",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4613818-biogen-highs-lows-mounting-expectations-ahead-of-leqembi-decision"
            }
        },
        {
            "id": "4597717",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-28T09:00:26-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1284442724/image_1284442724.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Biogen For Runups To Imminent Regulatory Decisions",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "452711",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4597717-buy-biogen-for-runups-to-imminent-regulatory-decisions"
            }
        },
        {
            "id": "4592672",
            "type": "article",
            "attributes": {
                "publishOn": "2023-04-06T11:51:32-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1141315747/image_1141315747.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Ionis And Biogen: Tofersen PDUFA Looms - Positive Outcome May Kick Off Bull Run For Both Stocks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "448409",
                            "type": "sentiment"
                        },
                        {
                            "id": "448410",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4592672-ionis-biogen-tofersen-pdufa-looms"
            }
        },
        {
            "id": "4587875",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-16T08:45:38-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/87467742/image_87467742.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen And Eisai's Leqembi: A Dose Of Reality For Alzheimer's Disease",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "97526",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "444222",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4587875-biogen-eisai-leqembi-dose-of-reality-alzheimers-disease"
            }
        },
        {
            "id": "4585099",
            "type": "article",
            "attributes": {
                "publishOn": "2023-03-07T02:47:50-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1368004903/image_1368004903.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen Should Resume Strong Growth With Zuranolone Approval",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "442221",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4585099-biogen-stock-should-resume-strong-growth-with-zuranolone-approval"
            }
        },
        {
            "id": "4575506",
            "type": "article",
            "attributes": {
                "publishOn": "2023-02-06T02:12:57-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359536024/image_1359536024.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Biogen: What To Do Ahead Of Q4 2022 Financial Report",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "435935",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4575506-biogen-stock-what-to-do-ahead-of-q4-earnings"
            }
        }
    ]
}